Skip to main content
Equibles
PTHS logo

PTHS · Pelthos Therapeutics Inc. · Metrics

Track PTHS — free

Use PTHS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTHS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.59 +0.89 (+4.76%) At close · Oct 22
Rebalance outlook locked
Going-concern doubt — cleared May 14, 2026

The latest filing states the doubt was alleviated.

“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”
View the 10-Q filed May 14, 2026
Market Cap
$71.59M
Shares
3.83M
Volume · Oct 22 79.8K Avg daily vol (3M) 61.99K

PTHS metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.59
Market cap
$71.59M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
-15.7%
Price change (3M)
-31.0%
Price change (6M)
-15.6%
Price change (YTD)
-36.8%
Price change (1Y)
-40.7%
Trailing year
Price change (5Y)
—
52-week high
$37.42
52-week low
$18.19
Change from 52-week high
-47.6%
Change from 52-week low
+7.7%
Annualized volatility
75.9%
Annualized volatility (3M)
68.7%
Beta
0.3
RSI (14D)
40.1
Price vs SMA 50
-14.1%
Price vs SMA 200
-20.3%
Avg volume (3M)
61,991
Relative volume
1.3
Average dollar volume
$1.53M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.7×
reciprocal yield 60.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-120.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
78.6%
Operating margin
-133.4%
Trailing 12 months
Net margin
-199.5%
Gross profit (TTM)
$34.03M
Operating profit (TTM)
−$57.78M
Net income (TTM)
−$86.39M
Trailing 12 months
Diluted EPS (TTM)
$-28.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$13.10
Gross profit per diluted share (TTM)
$10.29
Operating profit per diluted share (TTM)
$-17.67
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-26.36
Operating cash flow per diluted share (TTM)
$-13.09
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.39
Stock compensation per diluted share (TTM)
$2.83
Book value per share
$12.02

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$43.30M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+442.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-62.9%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-7.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.19M
Latest balance sheet
Cash & equivalents
$24.19M
Total assets
$137.36M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$42.30M
Capital expenditures (TTM)
$295,000
R&D (TTM)
$1.30M
SG&A (TTM)
$86.87M
Stock compensation (TTM)
$9.23M
R&D / revenue
3.0%
Stock compensation / revenue
21.3%

Ownership (13F)

9 metrics
13F filers
24
13F filer change QoQ
+7
Institutional ownership
34.6%
Conviction holders (share of 13F filers)
4.2%
Crowding (high-turnover and private-fund holders)
31.6%
Private-fund adviser ownership
22.1%
Active holders' share change QoQ
+49.4%
Holder tenure
2.9
Price vs estimated holder cost
+8.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.0%

Short interest

3 metrics
Short interest
2.7%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$44,939
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1919246 CUSIP 171126204 13F (30d) 1 filings 1 filers Visit website Investor relations